Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Mayer RJ, et al. Among authors: hochster h. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. N Engl J Med. 2015. PMID: 25970050 Free article. Clinical Trial.
Combining anti-VEGFR and anti-EGFR antibodies: Randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer:(ECOG-ACRIN E7208).
Hochster HS, Catalano P, Weitz M, Mitchell EP, Cohen D, O'Dwyer PJ, Faller BA, Kortmanky JS, O'Hara MH, Kricher SM, Lacy J, Lenz HJ, Verma U, Benson AB. Hochster HS, et al. J Natl Cancer Inst. 2024 May 22:djae114. doi: 10.1093/jnci/djae114. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 38775718
HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405.
Battaglin F, Ou FS, Qu X, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Ashouri K, Zemla TJ, Blanke CD, Venook AP, Kabbarah O, Lenz HJ, Innocenti F. Battaglin F, et al. Among authors: hochster hs. J Clin Oncol. 2024 Mar 8:JCO2301507. doi: 10.1200/JCO.23.01507. Online ahead of print. J Clin Oncol. 2024. PMID: 38457761
Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial.
Chiorean EG, Picozzi V, Li CP, Peeters M, Maurel J, Singh J, Golan T, Blanc JF, Chapman SC, Hussain AM, Johnston EL, Hochster HS. Chiorean EG, et al. Among authors: hochster hs. Cancer Med. 2023 Oct;12(20):20353-20364. doi: 10.1002/cam4.6621. Epub 2023 Oct 16. Cancer Med. 2023. PMID: 37840530 Free PMC article. Clinical Trial.
Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research.
Kumar R, Kim J, Deek MP, Eskander MF, Gulhati P, In H, Kennedy T, Shah MM, Grandhi MS, Berim L, Spencer KR, Langan RC, Hochster HS, Boland PM, Jabbour SK. Kumar R, et al. Among authors: hochster hs. Curr Oncol. 2023 Jul 5;30(7):6432-6446. doi: 10.3390/curroncol30070473. Curr Oncol. 2023. PMID: 37504333 Free PMC article. Review.
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C; FRESCO-2 Study Investigators. Dasari A, et al. Among authors: hochster hs. Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15. Lancet. 2023. PMID: 37331369 Clinical Trial.
Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial.
Ghidini M, Hochster H, Doi T, Van Cutsem E, Makris L, Takahashi O, Benhadji KA, Mansoor W. Ghidini M, et al. Among authors: hochster h. Gastric Cancer. 2023 Jul;26(4):626-637. doi: 10.1007/s10120-023-01393-2. Epub 2023 Apr 28. Gastric Cancer. 2023. PMID: 37106214 Free PMC article. Clinical Trial.
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
Catenacci DV, Kang YK, Uronis HE, Lee KW, Ng MC, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Oh DY, Yen J, Odegaard JI, Lagow E, Li D, Sun J, Kaminker P, Moore PA, Rosales MK, Park H. Catenacci DV, et al. Among authors: hochster hs. Oncology (Williston Park). 2023 Apr 25;37(4):176-183. doi: 10.46883/2023.25920992. Oncology (Williston Park). 2023. PMID: 37104758 Free article.
A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01).
Scott AJ, Basu Mallick A, Dotan E, Cohen SJ, Gold PJ, Hochster HS, Subramaniam S, Barzi A, Watts GS, Blatchford PJ, Messersmith WA. Scott AJ, et al. Among authors: hochster hs. Cancer Res Commun. 2022 Oct 14;2(10):1188-1196. doi: 10.1158/2767-9764.CRC-22-0169. eCollection 2022 Oct. Cancer Res Commun. 2022. PMID: 36969746 Free PMC article. Clinical Trial.
235 results